Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has earned an average recommendation of “Moderate Buy” from the sixteen brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $35.9167.
A number of brokerages have recently commented on DNLI. Deutsche Bank Aktiengesellschaft increased their target price on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Stifel Nicolaus set a $41.00 price objective on shares of Denali Therapeutics in a research note on Monday, June 22nd. BTIG Research reiterated a “buy” rating and issued a $39.00 price objective on shares of Denali Therapeutics in a report on Monday, May 11th. UBS Group raised their target price on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Friday, July 17th.
Denali Therapeutics Stock Performance
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $2.15 million. During the same period last year, the firm earned ($0.72) EPS. As a group, equities research analysts anticipate that Denali Therapeutics will post -2.73 EPS for the current fiscal year.
Institutional Investors Weigh In On Denali Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Denali Therapeutics during the second quarter worth about $26,000. Global Retirement Partners LLC acquired a new stake in shares of Denali Therapeutics during the 2nd quarter worth approximately $28,000. Headlands Technologies LLC purchased a new stake in shares of Denali Therapeutics during the 2nd quarter valued at approximately $26,000. Johnson Financial Group Inc. purchased a new stake in shares of Denali Therapeutics during the 3rd quarter valued at approximately $29,000. Finally, State of Wyoming acquired a new position in Denali Therapeutics in the second quarter valued at approximately $29,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.
Denali Therapeutics Company Profile
Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.
Featured Stories
- Five stocks we like better than Denali Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
